Glenmark Pharmaceuticals has informed that it has attached a media release on 24th March 2021 titled ‘Glenmark Pharmaceuticals receives ANDA approval for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity’ which is self-explanatory.
The above information is a part of company’s filings submitted to BSE.